CRISPR Therapeutics Reports $208.5M Q2 Loss, Activates 75 Global Treatment Centers

CRISPR Therapeutics AG reported its Q2 2025 financial results showing progress in clinical programs, including activating over 75 treatment centers for its CASGEVY® therapy and ongoing trials for next-generation CAR T cell therapies CTX112 and CTX131 targeting hematologic malignancies and autoimmune diseases. Despite a net loss of $208.5 million and revenue below expectations at $890K, the company's stock has risen over 60% in the last three months, supported by advancements in cardiovascular disease programs and inclusion in multiple indices. The company maintains a strong cash position of $1.7 billion but faces financial strain due to high R&D expenses and strategic investments. CRISPR is advancing its in vivo editing platform and conditioning programs aimed at broadening patient access and enhancing therapy convenience. Reimbursement agreements secured for sickle cell disease and beta-thalassemia patients in multiple countries further support market expansion. Analysts forecast substantial revenue growth despite anticipated continued unprofitability, reflecting investor optimism about CRISPR's clinical pipeline and market potential.